Anesthesiologists among physicians are on the top of the drug abuse list, and the mechanism is unclear. Recent studies suggest occupation-related second-hand exposure to i.v. drugs, including propofol, may play a role. Growing evidence indicates that propofol is one of the choices of drugs being abused. In this study, we show that propofol at minute concentrations increases glutamatergic excitatory synaptic transmission and discharges of dopamine neurons in the ventral tegmental area (VTA). We found that acute application of propofol (0.1-10 nM) to the VTA in midbrain slices of rats increased the frequency but not the amplitude of spontaneous excitatory postsynaptic currents (EPSCs) mediated by ␣-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors. We observed that propofol increased the amplitude but decreased the paired-pulse ratio of EPSCs evoked by stimulation in the absence and the presence of gabazine (SR 95531), a GABA A receptor antagonist. Moreover, the propofol-induced facilitation of EPSCs was mimicked by 6-phenyl-4-azabicyclo[5.4.0]undeca-7,9,11-triene-9,10-diol (SKF38393), an agonist of dopamine D 1 receptor, and by 1-[2-(diphenylmethoxy)ethyl]-4-(3-phenylpropyl)piperazine dihydrochloride (GBR 12935), a dopamine reuptake inhibitor, but blocked by (Ϯ)-7-bromo-8-hydroxy-3-methyl-1-phenyl-2,3,4, 5-tetrahydro-1H-3-benzazepine hydrochloride (SKF83566), a D 1 antagonist, or by depleting dopamine stores with reserpine. Finally, 1 nM propofol increased the spontaneous discharge rate of dopamine neurons. These findings suggest that propofol at minute concentrations enhances presynaptic D 1 receptormediated facilitation of glutamatergic synaptic transmission and the excitability of VTA dopamine neurons, probably by increasing extracellular dopamine levels. These changes in synaptic plasticity in the VTA, an addiction-related brain area might contribute to the development of propofol abuse and the increased susceptibility to addiction of other drugs.
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Drug abuse is a major social and health concern. Although physicians fully understand the consequences, some still abuse drugs. It is interesting to note that the drug abuse rate among physicians tends to be the highest for anesthesiologists (McAuliffe et al., 2006) . A recently proposed hypothesis on second-hand exposure might explain this trend (McAuliffe et al., 2006) . Chronic exposure to low levels of aerosolized i.v.-administered drugs, such as propofol, can potentially lead to a sensitization and later abuse of drugs (McAuliffe et al., 2006) . However, it is not clear how this exposure induces addiction.
Propofol is the most widely used i.v. drug for induction of general anesthesia. Although propofol has not traditionally been considered as a drug of abuse, growing evidence suggests that it may have an abuse potential. Patients anesthetized with propofol report experienced euphoria during recovery (Gepts et al., 1985) . Besides medical use, propofol is abused for recreational purpose. Nine human cases of abuse and dependence in anesthesiologists, nurses, and laypersons have been reported since 1992. Death occurred in four among these nine cases. Note that this number is certainly not representative of propofol abuse, as only serious cases have been reported (Roussin et al., 2007) . According to a recent survey, propofol abuse in academic anesthesiology has probably increased over the past 10 years. Eighteen percent of the anesthesiology programs in the United States have experienced one or more cases of propofol abuse or diversion in the past 10 years, and this percentage is possibly an underestimate because the challenges of detecting propofol abuse, as propofol is not a drug routinely tested for on urine (Wischmeyer et al., 2007) . Propofol abuse potential has also been supported by studies in human volunteers. Under blind conditions, 50% of the volunteers (6 or 12) chose propofol over placebo, and four of those six subjects chose propofol exclusively across three repeated trials (Zacny et al., 1993a,b) . Propofol abuse potential has also been supported by animal studies. Propofol is self-administered by baboons (Weerts et al., 1999) and rats (LeSage et al., 2000) . Conditioned-place preference for propofol has been established in rats (Pain et al., 1996) .
The mesolimbic dopamine system is a critically important component of the neuronal circuits mediating addiction. This system originates in the ventral tegmental area (VTA) and terminates in the nucleus accumbens (NAcc). All drugs of abuse enhance the activity of this dopamine circuit of reward (Nestler, 2005) . In previous rat studies, propofol has been found to alter dopamine levels in the NAcc (Pain et al., 2002) , suggesting that propofol may modify the activity of VTA dopamine neurons. However, the cellular mechanisms of the effects of propofol remain to be determined. Glutamatergic inputs to the VTA are the primary excitatory control of dopamine neurons. The purpose of current investigation was to determine whether minute concentrations of propofol can alter glutamatergic transmission and dopamine neuronal activity.
Materials and Methods
All experiments were performed in accordance with the guidelines outlined in the National Institutes of Health Guide for the Care and Use of Laboratory Animals, and they were approved by the Institutional Animal Care and Use Committee of the University of Medicine and Dentistry of New Jersey (Newark, NJ). The experiments were done on brains from Sprague-Dawley rats (postnatal days 10 -20).
Slice Preparation. The midbrain slices were prepared as described previously (Ye et al., 2004) . In brief, rats were anesthetized and then sacrificed by decapitation. Coronal midbrain slices (300 m in thickness) were cut using a VF-200 Slicer (Precisionary Instruments, Greenville, NC). Slices were prepared in ice-cold glycerolbased artificial cerebrospinal fluid containing 250 mM glycerol, 2.5 mM KCl, 1.2 mM NaH 2 PO 4 , 1.2 mM MgCl 2 , 2.4 mM CaCl 2 , 26 mM NaHCO 3 , and 11 mM glucose, and they were saturated with 95% O 2 , 5% CO 2 (carbogen). Slices (two/animal) were allowed to recover for at least 1 h in a holding chamber at 32°C in carbogen-saturated regular ACSF, which has the same composition as glycerol-based artificial cerebrospinal fluid, except that glycerol was replaced by 125 mM NaCl.
Electrophysiological Recording. Electrical signals were obtained in whole-cell patch-clamp configurations with MultiClamp 700A amplifiers (Molecular Devices, Union City, CA), a Digidata 1322A A/D converter (Molecular Devices), and pCLAMP 9.2 software (Molecular Devices). Data were filtered at 1 kHz, and they were sampled at 5 kHz. Neurons were voltage clamped at Ϫ70 mV to record ␣-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) receptor-mediated spontaneous and miniature excitatory postsynaptic currents (sEPSCs and mEPSCs). Current-clamp mode was used to record spontaneous firing. The patch electrodes had a resistance of 4 to 6 M⍀ when filled with a pipette solution containing 135 mM potassium gluconate, 5 mM KCl, 2 mM MgCl 2 , 10 mM HEPES, 2 mM Mg ATP, and 0.2 mM GTP. The pH of the pipette solution was adjusted to 7.2 with Tris-base. The experiments presented on Fig. 9 were done with a CsF-based pipette solution, which has the same composition as the potassium gluconate-based solution, except that potassium gluconate was replaced by 135 mM CsF. A single slice was transferred into a 0.4-ml recording chamber, and it was stabilized by a round platinum ring. Throughout the experiments, the bath was continually perfused with carbogenated ACSF (1.5-2.0 ml/min). Cells were visualized with an upright microscope (E600FN; Nikon, Tokyo, Japan) and near-infrared illumination. To evoke monosynaptic EPSCs (eEPSCs), the tip of a glass-stimulating pipette filled with 1 M NaCl was placed 50 to 100 m from the recorded neuron. Electrical stimuli (100 -200 s in duration) were applied at the rate of 0.05 Hz. Near the start of recording, an input/output curve was obtained. The stimulation was set to 20 to 30% of maximum, an intensity that evoked stable responses with no failures. Paired eEPSCs were elicited with a pair of identical stimuli separated by an interval of 20 ms. The series resistance (15-30 M⍀) or input resistance (300 -500 M⍀) was monitored throughout the whole-cell recording, and data were discarded if the resistance changed by more than 20%. All recordings were made at 32°C, maintained by an automatic temperature controller (Warner Instruments, Hamden, CT). In some experiments, brain slices were pretreated with 10 M reserpine for 90 min at 32°C to deplete endogenous monoamines (including dopamine).
All recordings were obtained from putative dopamine neurons identified by their pharmacological and physiological properties. In particular, VTA dopamine neurons were identified by the hyperpolarization response to 5 M U69593, an agonist of -opioid receptor (Fig. 1, A and B) . A previous study has showed that U69593 induced postsynaptic hyperpolarization in a subset of tyrosine hydroxylasestaining positive neurons (Margolis et al., 2003) . Moreover, a prom- inent voltage-sag (equivalent to the hyperpolarization current, I h , recorded in voltage-clamp mode) recorded in response to a hyperpolarizing current pulse (Ϫ130 pA) (Fig. 1C) confirmed the identity of dopamine neurons. Prominent I h is present in ϳ60% of VTA dopamine neurons, whereas VTA GABAergic neurons have no prominent I h (Lacey et al., 1990; Johnson and North, 1992) .
Chemicals and Applications. The chemicals, including 2,6-diisopropylphenol (propofol), gabazine (SR 95531), 2,3-dihydroxy-6,7-dinitroquinoxaline (DNQX), tetrodotoxin (TTX), U69593, methyl-11,17␣-dimethoxy-18␤- [(3,4,5-trimethoxybenzoyl) Data Analysis. sEPSCs and spontaneous firing were counted and analyzed using the MiniAnalysis program (Synaptosoft, Leonia, NJ). Spontaneous events (sEPSCs and mEPSCs) were screened automatically (5-pA amplitude threshold), checked visually, and accepted or rejected according to their rise and decay times. The frequency and amplitude of all events, during and after drug applications, were normalized to the mean of the values observed during the initial control period. Cumulative probability plots of the incidence of various interevent intervals and amplitudes, recorded in control conditions and during pharmacological manipulations from the same neuron, were analyzed with the Kolmogorov-Smirnov (K-S) test. For other plots, data obtained over a 1-to 2-min period at the peak of a drug response were normalized to the average values of sEPSC (or mEPSC) frequency and amplitude during the initial control period (1-2 min). Data were expressed as means Ϯ S.E.M. The statistical significance of drug effects was assessed by a paired two-tailed t test. Values of p Ͻ 0.05 were considered significant.
Results

Propofol at Minute Concentrations Enhances eEP-
SCs of Dopamine Neurons in the VTA. We first examined the effect of propofol on the EPSCs evoked by a local stimulating electrode from putative dopamine neurons at a holding potential (V H ) of Ϫ70 mV and in the presence of 10 M gabazine. These eEPSCs were mediated by glutamate AMPA receptors, as indicated by the complete blockage by 10 M DNQX ( Fig. 2A) . Unexpectedly, 1 nM propofol reversibly enhanced the amplitude of such eEPSCs by 32 Ϯ 6% (n ϭ 5, p ϭ 0.006 by paired t test; Fig. 2 , B and C, right panel). This enhancement suggests an increase in glutamatergic transmissions, which could be caused either by facilitation of presynaptic glutamate release, potentiation of postsynaptic glutamate receptors, or a combination. To distinguish between pre-and postsynaptic effects, we examined the paired-pulse ratio (PPR ϭ EPSC 2 /EPSC 1 ). Propofol (1 nM) significantly reduced the PPR, by 27 Ϯ 3%, from 2.0 Ϯ 0.3 before to 1.5 Ϯ 0.3 after propofol (n ϭ 5, p ϭ 0.02 by paired t test; Fig. 2D , right panel). Changes in transmitter release generally affect the PPR, as observed in several brain regions, including the VTA (Ye et al., 2004) .
Propofol at Minute Concentrations Increases the Frequency but Not the Amplitude of sEPSCs in VTA Dopamine Neurons. The above-mentioned results suggest that propofol increases presynaptic glutamate release. To further test this possibility, we examined sEPSCs recorded at a V H of Ϫ70 mV in the presence of 10 M gabazine from putative dopamine neurons in brain slices. As illustrated in Fig. 3A , 10 M DNQX eliminated the sEPSCs, indicating that they were mediated by AMPA receptors. Addition of 1 nM propofol significantly increased the frequency of sEPSCs (Fig. 3 , A, B 1 , and D 1 ) by 113 Ϯ 32% (from 0.5 Ϯ 0.1 to 1.0 Ϯ 0.2 Hz; n ϭ 5, p ϭ 0.02 by paired t test). The change in frequency is further shown by the significant increase in the probability of shorter intervals between successive sEPSCs (K-S test, p Ͻ 0.001; Fig. 3B 1 ) . After washout of propofol, the sEPSC frequency returned to the control level (Fig. 3 , A and C). However, 1 nM propofol did not alter the cumulative probability plot of sEPSC amplitudes (K-S test, p Ͼ 0.5; Fig.  3B 2 ) . In addition, propofol-induced increases in sEPSC frequency are dose-dependent: for propofol concentrations up to 1 nM, there was a progressive increase in sEPSC frequency (0.1 nM: 23 Ϯ 5%, n ϭ 4, p Ͻ 0.05 and 0.3 nM: 55 Ϯ 14%, n ϭ 
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6, p Ͻ 0.05); but at doses higher than 1 nM, propofol induced less increase in frequency (3 nM: 46 Ϯ 15%, n ϭ 4, p Ͻ 0.05 and 10 nM: 21 Ϯ 8%, n ϭ 6, p Ͻ 0.05). At even higher concentrations (1 M), propofol suppressed sEPSC frequency by 18 Ϯ 2% (n ϭ 3, p Ͻ 0.05; Fig. 3D 1 ) . In contrast, all concentrations of propofol (from 0.1 nM to 1 M) did not significantly alter the mean amplitudes of sEPSCs (0.1 nM: Ϫ0.4 Ϯ 7%, n ϭ 4, p Ͼ 0.8; 0.3 nM: 6 Ϯ 6%, n ϭ 6, p ϭ 0.6; 1 nM: 4 Ϯ 6%, n ϭ 5, p ϭ 0.8; 3 nM: 5 Ϯ 7%, n ϭ 4, p ϭ 0.4; 10 nM: 10 Ϯ 3%, n ϭ 6, p ϭ 0.07; and 1 M: Ϫ3 Ϯ 4%, n ϭ 3, p ϭ 0.6; Fig. 3D 2 ) . These data further support a presynaptic mechanism in the enhancement of glutamatergic transmission by minute concentrations of propofol.
Propofol Facilitation of Spontaneous EPSCs Depends on Sodium and Calcium Channels. We next tested the effect of propofol on spontaneous EPSCs recorded in the presence of 10 M gabazine and 1 M TTX, a blocker of sodium channels. Application of 1 M tetrodotoxin only slightly, albeit significantly, reduced the frequency of the spontaneous events (1.3 Ϯ 0.3 Hz in control, 1.0 Ϯ 0.5 Hz in 1 M tetrodotoxin; n ϭ 4, p Ͻ 0.05 by paired t test), but not their amplitude (18.1 Ϯ 1.8 pA in control, 17.0 Ϯ 1.9 pA in tetrodotoxin; n ϭ 5, p ϭ 0.22 by paired t test). In the presence of tetrodotoxin, 1 nM propofol did not significantly increase the frequency of the miniature EPSCs (by 9 Ϯ 7%, n ϭ 5, p ϭ 0.27; Fig. 4C 1 ) . We also tested the effect of 100 M cadmium, a nonselective blocker of voltage-gated calcium channels. The application of cadmium significantly reduced sEPSC frequency, by 58 Ϯ 8% (2.0 Ϯ 0.4 Hz in control, 0.8 Ϯ 0.2 Hz in cadmium; n ϭ 4; p ϭ 0.02 by paired t test), but not their amplitude (23.3 Ϯ 4.0 pA in control, 24.2 Ϯ 4.8 pA in cadmium; n ϭ 4, p ϭ 0.46 by paired t test). In the presence of cadmium, 1 nM propofol had no significant effect on sEPSC frequency (by 8.1 Ϯ 20.6%, n ϭ 4, p ϭ 0.63; Fig. 4C 2 ) . These data indicate that propofol action depends on both tetrodotoxin-sensitive sodium channels and voltage-gated calcium channels.
Propofol Facilitation of sEPSCs Is Eliminated by Dopamine D 1 R Antagonist. Dopamine D 1 Rs are expressed on VTA glutamatergic axons (Lu et al., 1997) . Previous in vivo study has shown that activation of D 1 Rs increases glutamate levels in the VTA (Kalivas and Duffy, 1995) . To test a possible involvement of D 1 Rs in propofol-induced facilitation of glutamatergic transmission, we compared the effects of propofol on sEPSC frequency in the absence and the presence of 10 M SKF 83566, a D 1 R antagonist. All sEPSCs were recorded in the presence of 10 M gabazine. As illustrated in Fig. 5 , although ineffective when applied alone, 10 M SKF 83566 suppressed the effects of 1 nM propofol. On five cells, 1 nM propofol slightly decreased sEPSC frequency by 0.3 Ϯ 4.0% (p ϭ 0.95; Fig. 5C 1 ) and amplitude by 12 Ϯ 5% (p ϭ 0.06; Fig. 5C 2 ) in the presence of 10 M SKF 83566. These results strongly suggest that D 1 Rs are an essential element in the mechanism of propofol-induced facilitation of glutamatergic transmission. D 1 R Agonist Mimics Propofol-Induced Facilitation of sEPSCs. To further test the involvement of D 1 Rs, we applied D 1 R agonist SKF 38393 to the VTA in slices. As illustrated in Fig. 6 , 10 nM SKF 38393 significantly increased sEPSC frequency, thus shortening intervals between successive sEPSCs (K-S test, p Ͻ 0.01; Fig. 6B ). The effect of SKF 38393 was reversible. The sEPSC frequency soon returned to its control level after washout (Fig. 6C) . As illus- Fig. 6D , the effects of SKF 38393 on sEPSC frequency were dose-dependent: 10, 100, 1000, and 3000 nM SKF 38393 increased sEPSC frequency by 45 Ϯ 8% (n ϭ 10, p Ͻ 0.01), 57 Ϯ 19% (n ϭ 5, p ϭ 0.01), 101 Ϯ 22% (n ϭ 6, p Ͻ 0.007), and 96 Ϯ 16% (n ϭ 5, p ϭ 0.004), respectively. No corresponding changes in sEPSC amplitude were produced by 10, 100, 1000, and 3000 nM SKF 38393: Ϫ2 Ϯ 7% (n ϭ 10, p ϭ 0.44), 6 Ϯ 12% (n ϭ 5, p ϭ 0.88), Ϫ0.1 Ϯ 10% (n ϭ 6, p ϭ 0.5), and Ϫ3 Ϯ 8% (n ϭ 5, p ϭ 0.74), respectively. These results, which closely parallel the effects of propofol, provide additional evidence for the presence of functional D 1 Rs on glutamatergic terminals. Dopamine Release Is Essential for Propofol-Induced Facilitation of eEPSCs. To determine whether dopamine release is necessary for propofol-induced facilitation of glutamatergic transmission, we applied propofol to slices in which dopamine was depleted by reserpine. As illustrated in Fig. 7 , 1 nM propofol was ineffective when applied to slices pretreated for 90 min with 10 M reserpine (Fig. 7A) , and propofol influenced neither the amplitudes of eEPSCs (by Ϫ7 Ϯ 15%; n ϭ 5, p ϭ 0.67) nor their paired-pulse ratio (by 10 Ϯ 15%, from 1.4 Ϯ 0.1 to 1.5 Ϯ 0.1; n ϭ 5, p ϭ 0.7).
Propofol-Induced Facilitation of sEPSCs Is Mimicked by a Dopamine Reuptake Blocker. Another, perhaps more important mechanism is suggested by previous evidence that acute administration of propofol (i.p. injection) elevates extracellular dopamine levels (Pain et al., 2002) . To elicit a rise in local dopamine levels in slices, we applied GBR 12935, a selective blocker of dopamine transporter. As illustrated in Fig. 8 , A to C, 20 nM GBR 12935 significantly and reversibly increased the frequency of sEPSCs recorded in VTA dopamine neurons (by 55 Ϯ 10%; n ϭ 12, p ϭ 0.002). Like propofol, GBR 12935 was ineffective in the presence of the D 1 R antagonist SKF 83566 at 10 M (the sEPSC frequency changed by Ϫ7 Ϯ 6%; n ϭ 5, p ϭ 0.16; Fig. 8, D-F) . This finding shows that a rise in local dopamine levels also mimics the action of propofol.
Propofol at Minute Concentrations Enhances eEPSCs in the Absence of Gabazine. GABA A receptor is a major target of propofol (Krasowski et al., 1998; Orser et al., 1998) . However, the above-mentioned experiments were conducted in the presence of gabazine, a GABA A receptor antagonist. To determine whether gabazine may alter the effect of propofol on EPSCs, we reexamined the effect of propofol on EPSCs in the absence of gabazine, using the CsF-based internal solution (see Materials and Methods) and at a V H of Ϫ60 mV. The postsynaptic responses to GABA or glycine were suppressed under these experimental conditions (Bormann et al., 1987) , allowing us to monitor propofol effect on EPSC. As illustrated in Fig. 9A , the evoked postsynaptic currents recorded under these experimental conditions were completely blocked by 10 M DNQX, indicating that they were the EPSCs mediated by AMPA receptors. Figure 9 , B and C, illustrates that 1 nM propofol enhanced the amplitude of evoked EPSCs and reduced the PPR (EPSC 2 /EPSC 1 ). These effects depend on the concentrations of propofol: 0.1, 0.3, 1, 3, and 1000 nM propofol increased the amplitude of evoked EPSCs (Fig. 9D 1 ) by: 15 Ϯ 7% (n ϭ 4, p ϭ 0.12), 30 Ϯ 9% (n ϭ 6, p ϭ 0.02), 41 Ϯ 6% (n ϭ 5, p ϭ 0.002), 27 Ϯ 4% (n ϭ 5, p ϭ 0.003), and Ϫ16 Ϯ 2% (n ϭ 7, p Ͻ 0.001), respectively, and reduced the PPR (Fig. 9D 2 ) by: 5 Ϯ 2% (n ϭ 4, p ϭ 0.046), 19 Ϯ 6% (n ϭ 6, p ϭ 0.03), 31 Ϯ 7% (n ϭ 5, p Ͻ 0.01), 21 Ϯ 6% (n ϭ 5, p ϭ 0.02), and Ϫ15 Ϯ 6% (n ϭ 7, p ϭ 0.05), respectively. Thus, propofol induces similar changes in EPSCs in the absence and the presence of gabazine.
Propofol (1 nM) Increases the Frequency of Spontaneous Firing of VTA Dopamine Neurons. Having established that minute concentrations of propofol facilitate glutamatergic transmission, we next assessed the physiological consequences of this action of propofol by examining the spontaneous firing of VTA dopamine neurons. As shown in Fig. 10 , 1 nM propofol reversibly increased the frequency of spontaneous firing of VTA dopamine neurons in brain slices by 33 Ϯ 7% (from 1.5 Ϯ 0.3 Hz in control to 1.9 Ϯ 0.4 Hz in propofol; n ϭ 7, p ϭ 0.005 by paired t test).
Discussion
Our major finding is that propofol at nanomolar concentrations increases glutamatergic transmissions to VTA and the excitability of VTA dopamine neurons. This finding is surprising because propofol is an anesthetic agent acts as a GABAergic drug (Krasowski et al., 1998; Orser et al., 1998) , and it has generally inhibitory effects on the brain. Furthermore, this intriguing action of propofol is mediated by D 1 Rs in glutamate-releasing terminals on VTA dopamine neurons.
Although a recent study found propofol concentration in the expired breath of patients is close to that in the plasma (Takita et al., 2007) , propofol concentration in the air of operating rooms has not been quantified. We speculate that it is very low and that the minute concentrations tested in current study coincide with the possibly very low concentrations of propofol in the air of operating rooms. Our finding may offer a plausible mechanism to the proposed hypothesis of second-hand exposure (McAuliffe et al., 2006) . Because glutamatergic transmissions play a major role in mediating behavioral manifestations of drug abuse (Kalivas, 1993) , propofol-induced enhancement of glutamatergic transmission in the VTA could be an important aspect underlying the development of propofol abuse.
Several lines of evidence indicate that propofol acts presynaptically to enhance glutamatergic transmission. Propofol increased sEPSC frequency, but it had no effect on the amplitude of sEPSCs and mEPSCs. Propofol enhanced the amplitude of stimulation-evoked EPSCs and decreased their paired-pulse ratio. All these effects point to a presynaptic mechanism of propofol action. Dopamine receptors, including both the D 2 family (in particular D 2 R) (Blum et al., 1990) and D 1 R are associated with drug dependence and abuse. For example, administration of D 1 R antagonist (Liu and Weiss, 2002) or disruption of D 1 R gene expression (El-Ghundi et al., 1998) prevents or attenuates alcohol-seeking behavior. Activation of D 1 R can increase glutamatergic transmission (Kalivas and Duffy, 1995) . Consistent with this report, in the current investigation, SKF 38393, a D 1 R agonist, dose-dependently increased the frequencies of sEPSCs without affecting their amplitudes. A similar effect was produced by an endogenous dopamine, induced by GBR 12935, a dopamine reuptake blocker. All these changes were abolished by SKF 83566, a D 1 R antagonist, which also eliminated the effects induced by propofol: increases the amplitude but decreases the paired-pulse ratio of evoked EPSCs. In keeping with a crucial involvement of dopamine was the suppression of the action of propofol when endogenous monoamines (including dopamine) were depleted by reserpine. All these findings support the notion that propofol increases glutamate transmission via the activation of D 1 Rs.
How does propofol activate presynaptic D 1 Rs? In the mid- Fig. 7 . Propofol (PRO)-induced increase in the eEPSCs is suppressed by dopamine depletion. Propofol (1 nM) has no effect on the amplitude (A) and paired-pulse ratio (EPSC 2 /EPSC 1 ) (B) of evoked EPSCs recorded in the VTA DA neurons in slices pretreated with reserpine for 90 min from five cells. C, summary of data from five cells in slices. brain, dopamine is released from the somatodendritic region of dopamine neurons (Björklund and Lindvall, 1975) . Dopamine molecules travel retrogradely across the synapse to bind to the D 1 Rs in the glutamate-releasing terminals. In reserpine-treated slices, in which dopamine was depleted, propofol failed to alter the amplitude and paired-pulse ratio of evoked EPSCs. This excludes the possibility that propofol directly activates presynaptic D 1 Rs. Propofol may raise local dopamine level. This possibility is supported by the similar effects of propofol and of dopamine reuptake blocker. A rise in local dopamine levels is also suggested by the bell-shaped dose dependence of propofol action. The diminishing potency of concentrations Ͼ1 nM cannot be explained by saturation of D 1 Rs at the site of action on glutamatergic terminals, because the selective D 1 R agonist was effective over a wide range of concentrations. One possible explanation is suggested by opposite effects of dopamine (the nonselective endogenous agonist) acting on different dopamine receptor subtypes. At low concentrations, dopamine seems to bind predominantly to D 1 Rs, and at higher concentrations it binds to D 2 Rs. For example, Trantham-Davidson et al. (2004) found that low concentrations of dopamine (Ͻ0.5 M) enhance inhibitory postsynaptic currents by activating mainly D 1 Rs, whereas higher concentrations of dopamine (Ͼ1 M) have the opposite effect of reducing inhibitory postsynaptic currents by predominantly activating D 2 Rs. In comparable experiments on EPSCs, Koga and Momiyama (2000) found that dopamine inhibits non-N-methyl-D-aspartate receptormediated evoked EPSCs in VTA dopamine neurons through presynaptic D 2 Rs, with a high IC 50 value of 16 M. The bell-shaped concentration dependence of propofol action in our slices is thus consistent with potentiation of dopamine release and opposite presynaptic actions via D 1 Rs and then D 2 Rs as the local dopamine rises. Our assumption that with minute concentrations of propofol local dopamine concentrations remain below the micromolar level, which predominantly activates D 1 Rs, is supported by previous evidence that electrical stimulation in the VTA does not raise extracellular dopamine levels above the submicromolar range (Kalivas and Duffy, 1991; Adell and Artigas, 2004) .
Propofol increases excitation of VTA dopamine neurons. VTA dopamine neurons receive numerous inputs that can modulate their eventual output. Integration of the synaptic inputs and the intrinsic properties sets the frequency and pattern of firing (Alberto et al., 2006) . As mentioned, glutamatergic afferents are the major excitatory inputs. Thus, the increase in glutamatergic transmission may contribute to the excitatory effect of minute concentrations of propofol on the dopamine neurons in the VTA.
Although many factors modulate glutamate release onto VTA dopamine neurons, the current study focused on the mechanism operating via presynaptic D 1 Rs because these receptors are involved in the rewarding action of abused drugs such as ethanol, and D 1 R activation enhances glutamate releases in the VTA. Furthermore, that a selective D 1 R antagonist eliminated propofol-induced elevation of glutamate transmission demonstrated the predominant role of D 1 Rs in propofol-induced increase in glutamate transmission in the VTA.
Although the main action of propofol is to potentiate GABAergic transmission (Krasowski et al., 1998; Orser et al., 1998) , the effect of minute concentrations of propofol on the EPSCs in the VTA seems independent of GABAergic action, because the effects of propofol on EPSCs were similar in presence and absence of gabazine, the GABA A receptor antagonist. Although the underlying mechanisms warrant further study, we propose that propofol at nanomolar concentrations may not be able to activate GABA A receptors, as a previous study in brain slices indicates that propofol activates GABA A receptors at concentrations Ն1 M (Shirasaka et al., 2004) . Nevertheless, our finding is in general agreement with a previous report that propofol effect on dopamine release in the NAcc is independent of GABA A receptors (Schulte et al., 2000) .
As mentioned, previous clinical trials performed by Zacny et al. (1993a,b) on healthy human volunteers have shown that the rewarding effect of propofol was observed only in a subgroup of treated people (half). In these studies, a discretetrial procedure was used. This procedure has been used with well known drugs of abuse, such as alcohol, amphetamines, ␦-9-tetrahydrocannabinol, or methylphenidate. As observed with propofol, although to a different extent, these other drugs were not clearly served as a reinforcer in a good number of volunteers tested (Uhlenhuth et al., 1981; de Wit et al., 1986; Stern et al., 1989; Chait and Zacny, 1992) .
Our in vitro data are in general agreement with a previous in vivo study regarding propofol alters the activity of the mesolimbic dopamine system. Nevertheless, in that in vivo microdialysis study, propofol increases extracellular dopamine levels in the NAcc only in subanesthetic and anesthetic doses (Pain et al., 2002) , which are in apparent conflict with our in vitro electrophysiological data in the VTA, where only minute concentrations of propofol increase EPSCs. We have no firm answer about the difference. Note that whereas electrophysiology measures synaptic release with high temporal and spatial resolution, microdialysis measures extrasynaptic outflow and reuptake. As suggested, propofol-increased dopamine in the NAcc might be the result of inhibition of dopamine reuptake (Pain et al., 2002) . Furthermore, several brain-imaging mappings of human and primate functioning found no activity in any midbrain area or limbic structures after the use of threshold, submaximal, or maximal doses of anesthetics (Heinke and Schwarzbauer, 2002) . Note that in these imaging studies, the effect of minute concentrations of propofol has not been tested.
The high sensitivity to propofol of the D 1 R-glutamatergic pathway unveiled in the current investigation may have particular significance in that anesthesiologists are exposure to trace amounts of general anesthetics in the air of the operating room. Furthermore, the changes in synaptic plasticity in the VTA, an addiction-related brain area, shown in the current investigation may not only contribute to the mechanism of the development of propofol abuse but also to the mechanism of the higher rate of drug abuse among anesthesiologists, because a history of exposure to one drug (such as propofol) can facilitate self-administration of another drug (such as cocaine) (Young, 1986) .
In conclusion, the present study shows that propofol at minute concentrations enhances presynaptic D 1 receptormediated facilitation of glutamatergic synaptic transmission and the excitability of VTA dopamine neurons, probably by increasing extracellular dopamine levels. The stimulating effect of minute concentrations of propofol on VTA dopamine neurons may contribute to the mechanisms underlying the development of propofol abuse. Furthermore, the proposed mechanism supports the hypothesis that physicians may become addicted to drugs through second-hand exposure. Through further study, preventive measures can be adopted to protect physicians and healthcare professionals.
